FAQ

phthalazinol

 

Topic mentions per year

Topic mentions per year

1976-2005
012319762005

Related topics

Related topics

3 relations

Narrower (1)

EG 626

Broader (2)

Phosphodiesterase InhibitorsPhthalazines

Related mentions per year

Related mentions per year

1946-2018
19401960198020002020
phthalazinol
Phosphodiesterase Inhibitors
Phthalazines
EG 626

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2005
2005
Prevention of Experimental Subarachnoid Hemorrhage-Induced Intracranial Arterial Vasonecrosis with Phosphodiesterase Inhibitor
Experiments in monkeys have demonstrated that the chronic vasospasm and arterial injury reaction produced by subarachnoid blood… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
1983
1983
Modification of angiotensin II-induced relaxation by dipyridamole, phthalazinol and aspirin in isolated dog renal arteries.
Angiotensin (ANG) II-induced relaxations in isolated dog renal and cerebral arteries are postulated to be mediated by the release… (More)
Is this relevant?
1980
1980
Effects of phthalazinol on smooth muscle cells of the porcine coronary artery and on neuromuscular junction on the guinea-pig vas deferens
In smooth muscle cells of the porcine coronary artery, phthalazinol (≦10−5 M) did not modify the membrane potential and the… (More)
  • figure 1
  • figure 2
  • figure 4
  • figure 5
  • table 1
Is this relevant?
1979
1979
Prevention of experimental subarachnoid hemorrhage-induced intracranial arterial vasonecrosis with phosphodiesterase inhibitor phthalazinol (EG-626).
Experiments in monkeys have demonstrated that the chronic vasospasm and arterial injury reaction produced by subarachnoid blood… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
1979
1979
Effects of phthalazinol (EG 626) on arterial lipolytic enzyme activities in the rat.
Phthalazinol (EG 626), a thromboxane A2 antagonist and cyclic AMP phosphodiesterase inhibitor, has been shown to prevent the… (More)
Is this relevant?
1978
1978
Prevention of persistent cerebral smooth muscle contraction in response to whole blood.
Using an in vitro system designed to measure arterial constriction, we have demonstrated the importance of platelet function in… (More)
  • figure 2
  • figure 1
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
1978
1978
Atherogenic mechanisms: enhancement of regression of atheromatous lesions by phthalazinol.
Atherosclerosis was produced in rabbits by feeding 1% cholesterol pellets for 15 weeks to 35 male rabbits divided into two equal… (More)
Is this relevant?
1977
1977
Phosphodiesterase inhibitors: their comparative effectiveness in vitro in various organs.
The inhibitor constants of several inhibitors for cyclic AMP- and cyclic GMP-phosphodiesterase from various organs are compared… (More)
Is this relevant?
1977
1977
Effect of phthalazinol (EG-626) on the mechanical activity and calcium influx of rabbit portal vein (1).
Phthalazinol (EG-626), a newly synthesized cyclic AMP phosphodiesterase inhibitor, inhibited spontaneous phasic contractions (SPC… (More)
Is this relevant?
1976
1976
Treatment of senile dementia and cerebellar disorders with phthalazinol. Cyclic AMP-increasing agent, phthalazinol, in therapeutic trials in hitherto incurable morbid conditions (I).
Three patients suffering from presenile dementia and two patients suffering from senile dementia were treated with phthalazinol… (More)
Is this relevant?